The Nascent Psychedelic Industry is Booming as Several Companies Have Gone Public and More are Expected to Follow This Route in 2021 to Attract More Capital From Institutional and Retail Investors
Competition among the dozens of biopharmaceutical companies is fierce. Many are seeking more capital to conduct expensive and lengthy drug trials and develop intellectual property to synthesize the molecules to help treat various mental disorders. The companies that can bring their Psychedelic drugs to the market first will emerge from the pack and could likely hit a home run. “Within the next six to 12 months, we will see an arms race in the psychedelic space as companies try to innovate and get their drugs to trials and to the market,” says Jason Spatafora, co-founder of MarijuanaStocks.com and head trader at TrueTradingGroup.com. ATAI Life Sciences, a Berlin-based biotech company that is researching both Psychedelic and nonpsychedelic compounds, is expected to go public in 2021
Last month, the first psychedelics ETF
Horizons Psychedelic Stock Index ETF (NEO: PSYK) began trading on the Canadian NEO exchange.
This is fertile ground for Zappy, who has a track record of getting in on the ground floor.
He left Bear Stearns in 1993 to work in infomercials. After that, he made investments during the dot-com boom, investing in web domains with URLs like Beer.com, Computer.com and CreditCards.com.
Today, much of Zappy s focus is on plant medicine and reform. However, psychedelics aren t a new endeavor for him.
Interest first came about when he learned of lab studies showing potential in treating suicide, addiction, anxiety and depression (the SAAD epidemic).
(6)
VANCOUVER, BC / ACCESSWIRE / February 6, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62)(WKN:A2P8K3) (the Company ) announces that it has engaged Donohoe Advisory Associates LLC ( Donohoe Advisory ) in connection with its efforts to seek a listing for its common shares on a NASDAQ Stock Market. The Company expects that listing its common shares on NASDAQ will provide increased investor awareness and market liquidity for shareholders.
Donohoe Advisory was founded by Dave Donohoe in 2004, and since that time the firm has successfully represented hundreds of companies in a wide range of listing matters for both the NASDAQ Stock Market and the New York Stock Exchange. Donohoe s senior advisory team have previously worked for either NASDAQ or the New York Stock Exchange (NYSE). Prior to forming Donohoe Advisory, Dave Donohoe spent over nine years with NASDAQ, where he ultimately served as Chief Counsel in the Listing Qualifications Department. Other senior advi
Core One Labs Engages Donohoe Advisory for Nasdaq Listing and Schedules Special Investor Call with Dr Robert E W Hancock to Demonstrate Recent Research Outcome pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.